Sign in
Active, not recruitingPhase 2

A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants

Key facts

Who runs it
Vaxcyte, Inc.
Where
Aurora, Bardstown, Brownsville, Charleston, Charlottesville, Cranberry Township, Dallas, Dayton, Erie, Gardena, Gordonsville, Gresham, Haughton, Houston, Idaho Falls, Jonesboro, Layton, League City, Lincoln, Los Angeles, Murray, N. Huntingdon, Ontario, Pensacola, Pittsburgh, Rexburg, Richmond, Roy, Simpsonville, South Euclid, South Jordan, Syracuse, Tampa, and West Covina, United StatesSee the 42 sitesAlso in 1 other country, 3 sites
Trial code
Status
Active, not recruiting
Phase
Phase 2
People taking part
900 people enrolled
Started
25 Nov 2024
Expected to end
Dec 2027
Type of study
Interventional, 5 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • 0.5 mL of the low dose VAX-31
  • 0.5 mL of the mid dose VAX-31
  • 0.5 mL of the high dose VAX-31
  • 0.5 mL dose of PCV20
  • 0.5 mL of the High-PFS dose VAX-31
Record updated
15 May 2026

Who can take part

Age
42 days to 89 days
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Healthy male or female infant ≥42 days to ≤89 days
  • Full-term infant at least 37 weeks gestational age at birth
  • Afebrile for ≥72 hours with an tympanic or rectal temperature <38.0°C (<100.4°F) before receipt of study vaccine.*Criterion applies to each vaccination. If not met, visit may be rescheduled for a time when no longer febrile for ≥72 hours
  • Able to attend all scheduled visits and comply with the study procedures
  • Subject's parent/legal guardian is able to read and understands the study procedures, alternate treatments, risks and benefits, and provides written informed consent
  • Subject's parent/legal guardian is able to fill out an eDiary of solicited AE and take daily tympanic temperature and measurements of local injection site reactions for the 7 days after each study vaccination
  • Subject's parent/legal guardian has an email address and access to a computer or smartphone with internet to complete the eDiary

Who cannot take part

  • Previous receipt of a licensed or investigational vaccine (excluding 1 dose of hepatitis B vaccine)
  • Use of any immunosuppressive therapy or planned use through the last blood draw (Visit 6). Receipt of a <14-day course of systemic corticosteroids is not exclusionary if completed ≥1 month prior to first study vaccination. Topical and inhaled/nebulized steroids are also permitted
  • History of failure to thrive or prior hospitalization for any chronic condition
  • Receipt of any investigational study product since birth, currently participating in another interventional investigational study, or plans to receive another investigational product while on study
  • History of invasive pneumococcal disease (positive blood culture, positive cerebrospinal fluid culture, or other sterile site) or known history of other culture positive pneumococcal disease
  • Known hypersensitivity to any vaccine
  • Known or suspected impairment of immunological function (e.g., asplenia, human immunodeficiency virus, primary immunodeficiency)
  • Subject has a bleeding disorder contraindicating IM vaccination
  • Subject or his/her mother has documented hepatitis B surface antigen-positive test
  • Subject has a known neurologic or cognitive behavioral disorder
  • Subject has a known clinically significant congenital malformation or serious chronic disorder
  • Receipt of a blood transfusion or blood products, including immunoglobulins
  • Any infant who cannot be adequately followed for safety according to the protocol plan
  • Any other reason that in the opinion of the Investigator may interfere with the evaluation required by the study

Where in United States

Also in 1 other country, 3 sites

  • Children's Hospital of Colorado - Dept. of Infectious DiseaseAurora, United States
  • Kentucky Pediatrics/Adult ResearchBardstown, United States
  • Proactive RGV LLCBrownsville, United States
  • Tribe Clinical Research, LLC dba Neighbors Clinical ResearchCharleston, United States
  • Pediatric Research of Charlottesville, LLCCharlottesville, United States
  • UPMC Children's Community Pediatrics - Bass Wolfson, CranberryCranberry Township, United States
  • Javara Inc. /Texas Health Care, PLLCDallas, United States
  • Oak Cliff Research CompanyDallas, United States
  • Ohio Pediatric Research AssociationDayton, United States
  • Allegheny Health & Wellness Pavilion WestErie, United States
  • Matrix Clinical ResearchGardena, United States
  • Pediatric Research of Charlottesville, LLCGordonsville, United States
  • Cyn3rgy ResearchGresham, United States
  • ACC Pediatric ResearchHaughton, United States
  • Kool Kids Pediatrics (Dynamed)Houston, United States
  • Mercury Clinical Research - Pediatric AssociatesHouston, United States
  • Sunrise PediatricsHouston, United States
  • Clinical Research Prime, LLPIdaho Falls, United States
  • The Children's Clinic of Jonesboro, P.AJonesboro, United States
  • AMR - LaytonLayton, United States
  • University of Texas Medical Branch - Sealy Institute for Vaccine Sciences, Clinical Trials ProgramLeague City, United States
  • Be Well Clinical Studies NebraskaLincoln, United States
  • Complete Children's HealthLincoln, United States
  • Matrix Clinical ResearchLos Angeles, United States
  • AMR - CottonwoodMurray, United States
  • UPMC Children's Community Pediatrics - NorwinN. Huntingdon, United States
  • Orange County Research InstituteOntario, United States
  • Sec Clinical ResearchPensacola, United States
  • UPMC Children's Community Pediatrics Bass Wolfson-Squirrel HillPittsburgh, United States
  • UPMC Children's Community Pediatrics South Hills-Jefferson HillsPittsburgh, United States
  • UPMC Children's Community Pediatrics-Castle ShannonPittsburgh, United States
  • UPMC Children's Hospital of Pittsburgh - General Academic Pediatrics (GAP)Pittsburgh, United States
  • Clinical Research Prime RexburgRexburg, United States
  • Clinical Research Partners, LLCRichmond, United States
  • Pediatric Center/Neutra Life SciencesRichmond, United States
  • AMR - RoyRoy, United States
  • Tribe Clinical Research/Parkside PediatricsSimpsonville, United States
  • Senders PediatricsSouth Euclid, United States
  • AMR South JordanSouth Jordan, United States
  • AMR - SyracuseSyracuse, United States
  • PAS ResearchTampa, United States
  • Center for Clinical Trials of San GabrielWest Covina, United States

About the trial

What the trial wants to find out

The objective of the study is to evaluate the safety, tolerability, and immunogenicity of 4 injections of VAX-31 (at 4 dose levels) compared to PCV20 in infants at 2, 4, 6, and 12-15 months of age, in addition to receiving routine US concomitant vaccines. Stage 1 of the study will comprise 3 dose ascending cohorts. Stage 2 of the study will enroll approximately 352 subjects. Stage 3 of the study will enroll approximately 500 subjects.

The 5 groups in the trial

  • VAX-31 LowTreatment being tested

    Participants will receive 4 doses of VAX-31 administered as an intramuscular injection at 2, 4, 6, and 12-15 months of age at one of four dose levels.

    Treatment: 0.5 mL of the low dose VAX-31

  • VAX-31 MidTreatment being tested

    Participants will receive 4 doses of VAX-31 administered as an intramuscular injection at 2, 4, 6, and 12-15 months of age at one of four dose levels.

    Treatment: 0.5 mL of the mid dose VAX-31

  • VAX-31 HighTreatment being tested

    Participants will receive 4 doses of VAX-31 administered as an intramuscular injection at 2, 4, 6, and 12-15 months of age at one of four dose levels.

    Treatment: 0.5 mL of the high dose VAX-31

  • PCV20Existing treatment, for comparison

    Participants will receive 4 doses of PCV20 administered as an intramuscular injection of the standard dose at 2, 4, 6, and 12-15 months of age.

    Treatment: 0.5 mL dose of PCV20

  • VAX-31 High-PFSTreatment being tested

    Participants will receive 4 doses of VAX-31 administered as an intramuscular injection at 2, 4, 6, and 12-15 months of age at one of four dose levels.

    Treatment: 0.5 mL of the High-PFS dose VAX-31

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 2, Randomized, Double-Blind, Active-Controlled, Dose-Finding Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants Given 4 Doses at 2, 4, 6, and 12-15 Months of Age Concomitantly With Routine Pediatric Vaccines
Record updated
15 May 2026